

150. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. *Cancer Res* 2011;71:614-24.
151. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. *Oncogene* 2009;28:2940-7.
152. Vlaicu P, Mertins P, Mayr T, Widschwendter P, Ataseven B, et al. Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator. *BMC Cancer* 2013;13:197.
153. Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, et al. The perivascular niche regulates breast tumour dormancy. *Nat Cell Biol* 2013;15:807-17.
154. Zhang J, Tian XJ, Zhang H, Teng Y, Li R, et al. TGF-beta-induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops. *Sci Signal* 2014;7:ra91.
155. West NR, Murray JI, Watson PH. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer. *Oncogene* 2014;33:1485-94.
156. Lu H, Clauser KR, Tam WL, Frose J, Ye X, et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. *Nat Cell Biol* 2014;16:1105-17.
157. Yu Y, Xiao CH, Tan LD, Wang QS, Li XQ, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling. *Br J Cancer* 2014;110:724-32.
158. Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? *Cell Stem Cell* 2015;16:225-38.
159. Grosse-Wilde A, Fouquier d'Herouel A, McIntosh E, Ertaylan G, Skupin A, et al. Stemness of the hybrid epithelial/mesenchymal state in breast cancer and its association with poor survival. *PLoS One* 2015;10:e0126522.
160. Shibue T, Weinberg RA. Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. *Proc Natl Acad Sci U S A* 2009;106:10290-5.
161. Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, et al. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. *PLoS One* 2009;4:e7181.
162. Ocana OH, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. *Cancer Cell* 2012;22:709-24.
163. Del Pozo Martin Y, Park D, Ramachandran A, Ombrato L, Calvo F, et al. Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization. *Cell Rep* 2015;13:2456-69.
164. Ge Y, Fuchs E. Stretching the limits: from homeostasis to stem cell plasticity in wound healing and cancer. *Nat Rev Genet* 2018;19:311-25.
165. Thiery JP, Chopin D. *Cancer and Metastasis Reviews* 1999;18:31-42.
166. Varga J, Greten FR. Cell plasticity in epithelial homeostasis and tumorigenesis. *Nat Cell Biol* 2017;19:1133-41.
167. Hay ED. An overview of epithelio-mesenchymal transformation. *Acta Anat (Basel)* 1995;154:8-20.
168. Shook D, Keller R. Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. *Mechanisms of Development* 2003;120:1351-83.
169. Levayer R, Lecuit T. Breaking down EMT. *Nat Cell Biol* 2008;10:757-9.
170. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. *Nat Rev Mol Cell Biol* 2006;7:131-42.
171. Rodilla V, Fre S. Cellular plasticity of mammary epithelial cells underlies heterogeneity of breast cancer. *Biomedicines* 2018;6.
172. Van Keymeulen A, Lee MY, Ousset M, Brohee S, Rorive S, et al. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. *Nature* 2015;525:119-23.
173. Koren S, Reavie L, Couto JP, De Silva D, Stadler MB, et al. PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. *Nature* 2015;525:114-8.
174. Celia-Terrassa T. Mammary stem cells and breast cancer stem cells: molecular connections and clinical implications. *Biomedicines* 2018;6.
175. Gjorevski N, Nelson CM. Integrated morphodynamic signalling of the mammary gland. *Nature Reviews Molecular Cell Biology* 2011;12:581-93.
176. Godde NJ, Galea RC, Elsum IA, Humbert PO. Cell polarity in motion: redefining mammary tissue organization through EMT and cell polarity transitions. *J Mammary Gland Biol Neoplasia* 2010;15:149-68.
177. Merrell AJ, Stanger BZ. Adult cell plasticity in vivo: de-differentiation and transdifferentiation are back in style. *Nat Rev Mol Cell Biol* 2016;17:413-25.
178. Ye X, Weinberg RA. Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. *Trends in Cell Biology* 2015;25:675-86.
179. Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. *Genes Dev* 2009;23:2563-77.
180. Mun GI, Boo YC. Identification of CD44 as a senescence-induced cell adhesion gene responsible for the enhanced monocyte recruitment to senescent endothelial cells. *Am J Physiol Heart Circ Physiol* 2010;298:H2102-11.
181. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. *Breast Cancer Res* 2008;10:R53.
182. Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. *Exp Biol Med (Maywood)* 2013;238:324-38.
183. Morath I, Hartmann TN, Orian-Rousseau V. CD44: More than a mere stem cell marker. *Int J Biochem Cell Biol* 2016;81:166-73.
184. Gewirtz DA, Alotaibi M, Yakovlev VA, Povirk LF. Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition.

- Radiat Res 2016;186:327-32.
185. Alotaibi M, Sharma K, Saleh T, Povirk LF, Hendrickson EA, et al. Radiosensitization by PARP inhibition in DNA repair proficient and deficient tumor cells: proliferative recovery in senescent cells. *Radiat Res* 2016;185:229-45.
 186. Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, et al. The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice. *Mol Cancer Ther* 2011;10:2320-9.
 187. Shelton JW, Waxweiler TV, Landry J, Gao H, Xu Y, et al. In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells. *Int J Radiat Oncol Biol Phys* 2013;86:469-76.
 188. Tlsty TD, Crawford YG, Holst CR, Fordyce CA, Zhang J, et al. Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis. *J Mammary Gland Biol Neoplasia* 2004;9:263-74.
 189. Jiang Z, Jones R, Liu JC, Deng T, Robinson T, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. *Cell Cycle* 2011;10:1563-70.
 190. Bendris N, Cheung CT, Leong HS, Lewis JD, Chambers AF, et al. Cyclin A2, a novel regulator of EMT. *Cell Mol Life Sci* 2014;71:4881-94.
 191. Emadi Baygi M, Soheili ZS, Schmitz I, Sameie S, Schulz WA. Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines. *Cell Biol Toxicol* 2010;26:553-67.
 192. Wang T, Li Y, Wang W, Tuerhanjiang A, Wu Z, et al. Twist2, the key Twist isoform related to prognosis, promotes invasion of cervical cancer by inducing epithelial-mesenchymal transition and blocking senescence. *Hum Pathol* 2014;45:1839-46.
 193. Smit MA, Peeper DS. Deregulating EMT and senescence: double impact by a single twist. *Cancer Cell* 2008;14:5-7.
 194. Ansieau S, Courtois-Cox S, Morel AP, Puisieux A. Failsafe program escape and EMT: a deleterious partnership. *Semin Cancer Biol* 2011;21:392-6.
 195. de Carne Trecesson S, Guillemin Y, Belanger A, Bernard AC, Preisser L, et al. Escape from p21-mediated oncogene-induced senescence leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteins. *J Biol Chem* 2011;286:12825-38.
 196. Weinberg RA. Twisted epithelial-mesenchymal transition blocks senescence. *Nat Cell Biol* 2008;10:1021-3.
 197. Salmina K, Jankevics E, Huna A, Perminov D, Radovica I, et al. Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells. *Exp Cell Res* 2010;316:2099-112.
 198. Chitikova ZV, Gordeev SA, Bykova TV, Zubova SG, Pospelov VA, et al. Sustained activation of DNA damage response in irradiated apoptosis-resistant cells induces reversible senescence associated with mTOR downregulation and expression of stem cell markers. *Cell Cycle* 2014;13:1424-39.
 199. Le Duff M, Gouju J, Jonchere B, Guillon J, Toutain B, et al. Regulation of senescence escape by the cdk4-EZH2-AP2M1 pathway in response to chemotherapy. *Cell Death Dis* 2018;9:199.
 200. Milanovic M, Fan DNY, Belenki D, Dabritz JHM, Zhao Z, et al. Senescence-associated reprogramming promotes cancer stemness. *Nature* 2018;553:96-100.
 201. Barreto-Andrade JC, Efimova EV, Mauceri HJ, Beckett MA, Sutton HG, et al. Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. *Mol Cancer Ther* 2011;10:1185-93.
 202. Wu PC, Wang Q, Grobman L, Chu E, Wu DY. Accelerated cellular senescence in solid tumor therapy. *Exp Oncol* 2012;34:298-305.
 203. Mathiesen RR, Borgen E, Renolen A, Lokkevik E, Nesland JM, et al. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. *Breast Cancer Res* 2012;14:R117.
 204. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, et al. Systemic spread is an early step in breast cancer. *Cancer Cell* 2008;13:58-68.
 205. Heitzer E, Perakis S, Geigl JB, Speicher MR. The potential of liquid biopsies for the early detection of cancer. *NPJ Precis Oncol* 2017;1:36.
 206. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. *Cell* 2010;140:62-73.
 207. Doherty MR, Smigiel JM, Junk DJ, Jackson MW. Cancer Stem Cell Plasticity Drives Therapeutic Resistance. *Cancers (Basel)* 2016;8.
 208. Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, et al. Identification of the tumour transition states occurring during EMT. *Nature* 2018;556:463-8.
 209. Goldman A, Majumder B, Dhawan A, Ravi S, Goldman D, et al. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. *Nat Commun* 2015;6:6139.
 210. Biddle A, Liang X, Gammon L, Fazil B, Harper LJ, et al. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. *Cancer Res* 2011;71:5317-26.
 211. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. *Clin Cancer Res* 2009;15:2657-65.
 212. Sun L, Yao Y, Liu B, Lin Z, Lin L, et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BM11. *Oncogene* 2012;31:432-45.
 213. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. *Cell* 2010;141:69-80.
 214. Pisco AO, Huang S. Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'What does not kill me strengthens me'. *Br J Cancer* 2015;112:1725-32.
 215. Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes

- chemoresistance in triple negative breast cancer. *Nat Commun* 2018;9:2897.
216. Hui M, Cazet A, Nair R, Watkins DN, O'Toole SA, et al. The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. *Breast Cancer Res* 2013;15:203.
 217. O'Toole SA, Machalek DA, Shearer RF, Millar EK, Nair R, et al. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. *Cancer Res* 2011;71:4002-14.
 218. Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. *Nat Med* 2013;19:1410-22.
 219. Chuang PT, Kawcak T, McMahon AP. Feedback control of mammalian Hedgehog signaling by the Hedgehog-binding protein, Hip1, modulates Fgf signaling during branching morphogenesis of the lung. *Genes Dev* 2003;17:342-7.
 220. Yu H, Jove R. The STATs of cancer--new molecular targets come of age. *Nat Rev Cancer* 2004;4:97-105.
 221. Turkson J. STAT proteins as novel targets for cancer drug discovery. *Expert Opin Ther Targets* 2004;8:409-22.
 222. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. *Clin Cancer Res* 2002;8:945-54.
 223. Kolosenko I, Yu Y, Busker S, Dyczynski M, Liu J, et al. Identification of novel small molecules that inhibit STAT3-dependent transcription and function. *PLoS One* 2017;12:e0178844.
 224. Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. *Leukemia* 2015;29:586-97.
 225. Liu F, Cao J, Wu J, Sullivan K, Shen J, et al. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. *J Invest Dermatol* 2013;133:2041-9.
 226. Sunayama J, Matsuda K, Sato A, Tachibana K, Suzuki K, et al. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. *Stem Cells* 2010;28:1930-9.
 227. Dubrovskaya A, Kim S, Salamone RJ, Walker JR, Maira SM, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. *Proc Natl Acad Sci U S A* 2009;106:268-73.
 228. Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. *Cancer Cell* 2013;23:406-20.
 229. Baselga J, Im S-A, Iwata H, Cortés J, De Laurentiis M, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2017;18:904-16.
 230. Anderson EJ, Mollon L, Dean JL, Aguilar A, Davis LE, et al. A systematic literature review of the clinical prognosis of HR+/HER2-advanced or metastatic breast cancer with and without PIK3CA mutation. *J Clin Oncol* 2018;36.
 231. Baselga J, Dent SF, Cortés J, Im Y-H, Diéras V, et al. Phase III study of taselelisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): primary analysis from SANDPIPER. *J Clin Oncol* 2018;36:LBA1006.
 232. Sharma P, Abramson VG, O'Dea A, Lewis S, Scott JN, et al. Abstract P6-11-08: Safety and efficacy results from phase I study of BYL 719 plus nab-paclitaxel in HER 2 negative metastatic breast cancer. *Cancer Res* 2017;77:P6-11-08.
 233. Zhou J, Wulfskuhle J, Zhang H, Gu P, Yang Y, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. *Proc Natl Acad Sci U S A* 2007;104:16158-63.
 234. Douville J, Beaulieu R, Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells. *Stem Cells Dev* 2009;18:17-25.
 235. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. *Cancer Res* 2009;69:3382-9.
 236. Chang WW, Lin RJ, Yu J, Chang WY, Fu CH, et al. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors. *Breast Cancer Res* 2013;15:R39.
 237. Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB, et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. *Oncogene* 2013;32:209-21.
 238. Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, et al. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. *Breast Cancer Res Treat* 2012;136:717-27.
 239. Ekyalongo RC, Yee D. Revisiting the IGF-1R as a breast cancer target. *NPJ Precis Oncol* 2017;1.
 240. Liu Y, Zhang X, Liu J, Hou G, Zhang S, et al. Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study. *Tumour Biol* 2014;35:1275-86.
 241. Zhu Y, Zhang X, Liu Y, Zhang S, Liu J, et al. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo. *Tumour Biol* 2012;33:1349-62.
 242. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. *Cancer Res* 2011;71:3196-201.
 243. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. *Cell* 2009;138:645-59.
 244. Kumar D, Shankar S, Srivastava RK. Rottlerin-induced autophagy leads to the apoptosis in breast cancer stem cells: molecular mechanisms. *Mol Cancer* 2013;12:171.
 245. Kolev VN, Wright QG, Vidal CM, Ring JE, Shapiro IM, et al. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells. *Cancer Res* 2015;75:446-55.
 246. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. *Cancer Res* 2005;65:8530-7.
 247. D'Angelo RC, Ouzounova M, Davis A, Choi D, Tchuensam SM, et al. Notch reporter activity in breast cancer cell lines identifies a

- subset of cells with stem cell activity. *Mol Cancer Ther* 2015;14:779-87.
248. Parr C, Watkins G, Jiang WG. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. *Int J Mol Med* 2004;14:779-86.
 249. Zhang J, Shao X, Sun H, Liu K, Ding Z, et al. NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling. *Oncotarget* 2016;7.
 250. Chen J, Chang H, Peng X, Gu Y, Yi L, et al. 3,6-dihydroxyflavone suppresses the epithelial-mesenchymal transition in breast cancer cells by inhibiting the Notch signaling pathway. *Sci Rep* 2016;6:28858.
 251. Mao L. NOTCH mutations: multiple faces in human malignancies. *Cancer Prev Res (Phila)* 2015;8:259-61.
 252. Zhang X, Zhao X, Shao S, Zuo X, Ning Q, et al. Notch1 induces epithelial-mesenchymal transition and the cancer stem cell phenotype in breast cancer cells and STAT3 plays a key role. *Int J Oncol* 2015;46:1141-8.
 253. Hui C, Yujie F, Lijia Y, Long Y, Hongxia X, et al. MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis. *Breast Cancer Res* 2012;14:R80.
 254. Diluvio G, Del Gaudio F, Giuli MV, Franciosa G, Giuliani E, et al. NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest. *Oncogenesis* 2018;7:42.
 255. Wang X, Jung YS, Jun S, Lee S, Wang W, et al. PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness. *Nat Commun* 2016;7:10633.
 256. Gujral TS, Chan M, Peshkin L, Sorger PK, Kirschner MW, et al. A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. *Cell* 2014;159:844-56.
 257. Jang GB, Hong IS, Kim RJ, Lee SY, Park SJ, et al. Wnt/beta-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells. *Cancer Res* 2015;75:1691-702.
 258. Kim JY, Lee HY, Park KK, Choi YK, Nam JS, et al. CWP232228 targets liver cancer stem cells through Wnt/beta-catenin signaling: a novel therapeutic approach for liver cancer treatment. *Oncotarget* 2016;7:20395-409.
 259. Demaria M, O'Leary MN, Chang J, Shao L, Liu S, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. *Cancer Discov* 2017;7:165-76.
 260. Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. *Cell* 2017;169:132-47.e16.
 261. Lee M, Lee JS. Exploiting tumor cell senescence in anticancer therapy. *Bmb Reports* 2014;47:51-9.
 262. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. *Nat Rev Cancer* 2011;11:503-11.
 263. Muñoz-Espín D, Rovira M, Galiana I, Giménez C, Lozano-Torres B, et al. A versatile drug delivery system targeting senescent cells. *EMBO Mol Med* 2018;10:e9355.
 264. Zhu Y, Tchkonina T, Fuhrmann-Stroissnigg H, Dai HM, Ling YY, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. *Aging Cell* 2016;15:428-35.
 265. Chang J, Wang Y, Shao L, Laberge RM, Demaria M, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. *Nat Med* 2016;22:78-83.
 266. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. A quantitative analysis of kinase inhibitor selectivity. *Nat Biotechnol* 2008;26:127-32.
 267. Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, et al. Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. *NPJ Breast Cancer* 2018;4:10.